| 000 | 01802 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514021534.0 | ||
| 264 | 0 | _c20020201 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.2002.20.1.274 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMikulski, Stanislaw M | |
| 245 | 0 | 0 |
_aPhase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJan 2002 |
||
| 300 |
_a274-81 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesothelioma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aRibonucleases _xadverse effects |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aCostanzi, John J | |
| 700 | 1 | _aVogelzang, Nicholas J | |
| 700 | 1 | _aMcCachren, Spence | |
| 700 | 1 | _aTaub, Robert N | |
| 700 | 1 | _aChun, Hoo | |
| 700 | 1 | _aMittelman, Abraham | |
| 700 | 1 | _aPanella, Timothy | |
| 700 | 1 | _aPuccio, Carmelo | |
| 700 | 1 | _aFine, Robert | |
| 700 | 1 | _aShogen, Kuslima | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 20 _gno. 1 _gp. 274-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2002.20.1.274 _zAvailable from publisher's website |
| 999 |
_c11685154 _d11685154 |
||